Zydus Lifesciences- first in India to launch protection against new strain of influenza virus

VaxiFlu-4 was developed at Zydus' Vaccine Technology Centre (VTC) in Ahmedabad and received clearance from the Central Drug Laboratory (CDL). It will be marketed by Zydus Vaxxicare, a division of the group focusing on preventive healthcare.

"Preventives are key to public health, and vaccines have the potential to improve the quality of life," said Dr Sharvil Patel, Managing Director, Zydus Lifesciences Limited. "In India, there is a pressing need for access to affordable, high-quality vaccines. With vaccines like VaxiFlu-4, we are serving the cause of public health through annual immunisation and preventing flu outbreaks."

Revenue increased by 6.10% to ₹2,515.90 crore in the December 2024 quarter, compared to ₹2,371.30 crore in the year-ago period. Profit grew by 4.48% to ₹470.60 crore from ₹450.40 crore. Operating Profit declined sharply to ₹726 crore from ₹805.90 crore in the corresponding previous quarter.

Quadrivalent vaccines offer broader protection than traditional trivalent vaccines by covering strains of both influenza A and influenza B, significantly reducing the risk of vaccine mismatch. Shares of Zydus Lifescience closed 1.07% lower at ₹881 apiece on the NSE.